Polysomnography was recorded and blood samples were drawn for determination of adrenocorticotropic hormone (ACTH) and cortisol during the entire night.
Fasting blood samples were drawn for determination of glucose, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and uric acid using enzymatic methods.
Within 24 hours after the development of delirium, blood was drawn for determination of biomarkers.
At t = 0 h (08 00 hours), blood samples were drawn for determination of background enrichments.
Venous blood was drawn for determination of pharmacokinetic profiles for olaparib and dacarbazine when dosed alone and in combination.
Venous blood was drawn for determination of PK profiles for olaparib when dosed alone and in combination with bevacizumab.
Blood samples drawn for determination of cytokines and biomarkers of endothelial dysfunction were stored at -70°C before laboratory testing.
Arterial blood samples were drawn for determination of radioactivity in whole blood and plasma as well as for analysis of unchanged radioligand in plasma [ 7].
At T = 0 00, T = 3 00 and from T = 5 40 until T = 6 00 every 10 min blood samples were drawn for determination of the concentration of plasma insulin.
After a 4-week period of recovery, blood samples were drawn for determination of sex hormones (RIA oestradiol and total testosterone assays; Immunotech) and rat progenitor cell count.
Blood (6 ml citrated, 10 ml serum and 4 ml Ethylendiamin-tetraacetat (EDTA)) was routinely drawn for determination of coagulation hemoglobin and safety parameters before application of PCC.
